相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
33.3%
已完成
1
33.3%
Unknown
1
33.3%
暂无批准数据
- Head and neck squamous cell carcinoma cases are projected to increase from 229,000 to 273,000 across eight major markets by 2034, with frail and elderly patients representing 44% of cases. - Three emerging therapies—JNJ-1900, Akalux, and Steboronine—offer new treatment options for patients who cannot tolerate intensive surgery, radiation, and platinum-based chemotherapy. - JNJ-1900 is positioned for broadest global impact with projected sales of $108 million by 2034, while Akalux targets $77.6 million in sales across the same timeframe. - These treatments focus on improving locoregional control while minimizing systemic toxicity that makes standard regimens intolerable for vulnerable patient populations.
- The National Cancer Center Japan will conduct a Phase I/II basket trial of Boron Neutron Capture Therapy (BNCT) for unresectable and recurrent thoracic malignant solid tumors. - This trial is the first of its kind to evaluate BNCT across multiple thoracic cancer types, aiming to expedite development by grouping cancers with shared organs at risk. - The study will assess the safety and efficacy of BNCT, along with the utility of [18F]F-BPA PET imaging in determining patient suitability for BNCT. - The collaboration involves Sumitomo Heavy Industries, STELLA PHARMA CORPORATION, and Cancer Intelligence Care Systems, with the trial period extending until October 2028.
